11550 Background: Topotecan and pazopanib (PAZ) individually have clinical benefit in patients (pts) with sarcomas. PAZ is a multi-tyrosine kinase inhibitor and topotecan affects endothelial cells, and inhibits HIF-1, an upstream regulator of VEGF expression. The utilization of PAZ with topotecan is anticipated to produce anti-tumor synergism in pts with sarcomas. Methods: A phase II study of PAZ/topotecan in pts with metastatic and non-resectable bone and soft tissue sarcomas (STS) was conducted by the Midwest Sarcoma Trials Partnership. Age > 18, ECOG ≤1, adequate organ function, measurable disease and 1 prior therapy were required. Pts were treated with PAZ 800mg oral daily, Topotecan 8mg orally day 1, 8, 15 on a 28-day cycle until disease progression or unacceptable toxicity. Pts enrolled in 3 cohorts: 1. STS non-liposarcoma 2. osteosarcoma 3. liposarcoma. Primary endpoint: progression-free rate (PFR) at 12 weeks in cohort 1. Secondary endpoints: overall response rate (ORR), clinical benefit rate (CBR), OS, median progression free survival (PFS), PFR at 12 weeks in cohort 2 and 3, and safety and tolerability. Lab correlates evaluated PFR and OS to levels of VEGFR2 and PDGF. Simon 2-stage design was used for cohort 1. Results: A total of 139 pts were enrolled at 6 sites, with 121 evaluable for response. Data per cohorts 1,2, and 3: # of pts- 103, 17 and 19; mean age- 56, 41, 57; % female- 63, 53, 32%; 1-2 prior therapies- 75, 65, 84%. PFR at 12 weeks is 57.5%, 62.5%, 31.3% with a median PFS of 4.4, 4.5, 1.4 months and OS of 9.8, 11.1, 12.3 months. ORR is 8,6,0 % and CBR is 74, 88, 38%. Grade 3-4 adverse events (%): neutropenia (42), thrombocytopenia (29), hypertension (16) and anemia (12). Pts in cohort 1 who progressed within 6 weeks received 61% of prescribed PAZ dose vs. 67% for those with did not progress. Histologies in cohort 1- LMS (49%), UPS (15%), synovial (10%). Correlative data will be presented. Conclusions: The combination of PAZ/topotecan produced identical results to historical data for PAZ alone in pts with STS, except with a worse toxicity profile. For pts with osteosarcoma, the combination proved extremely promising and cohort 2 will be expanded. The combination was ineffective in liposarcoma. Clinical trial information: NCT02357810.